[Skip to Navigation]
Views 6,720
Citations 0
Editorial
June 21, 2021

Overuse of Levothyroxine in Patients With Subclinical Hypothyroidism: Time to “Leve”-Out-Thyroxine

Author Affiliations
  • 1Sunnybrook Health Sciences Centre, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  • 2Teachable Moments Editorial Fellow, JAMA Internal Medicine
  • 3Department of Medicine, University of California, San Francisco
  • 4Deputy Editor, JAMA Internal Medicine
JAMA Intern Med. Published online June 21, 2021. doi:10.1001/jamainternmed.2021.2690

Recent clinical trials1,2 and a meta-analysis3 demonstrate no symptomatic benefit from treatment with levothyroxine among nonpregnant adults with subclinical hypothyroidism (defined as an elevated thyrotropin level with normal serum thyroid hormone levels). Contemporary evidence-based clinical practice guidelines strongly advise against levothyroxine supplementation for subclinical hypothyroidism.3,4 Older guidelines from professional societies generally do not recommend treatment for subclinical hypothyroidism with a thyrotropin level less than 10 mIU/L, except in special circumstances.5,6

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×